Overview
What is Benaroya Research Institute At Virginia Mason?
Benaroya Research Institute at Virginia Mason is a nonprofit organization based in Seattle, Washington, dedicated to advancing the science that predicts, prevents, reverses, and cures diseases of the immune system. The institute's primary focus is on interventional immunology, with a significant portion of their funding coming from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). They lead the Immune Tolerance Network (ITN), a research consortium with a mission to develop new tolerogenic approaches for the treatment and prevention of diseases in three clinical areas: asthma and allergic diseases, autoimmune diseases, and immune-mediated rejection of transplanted solid organs, tissues, and cells. The institute manages the overall grant from NIAID, overseeing the infrastructure and coordinating activities across the network. They have recently renewed their grant for a second cycle, totaling approximately $27 million annually, and have established relationships and collaborations within the research community. Benaroya Research Institute also conducts research on type 1 diabetes, seeking ways to predict and prevent the disease before clinical symptoms occur, and supports the Type 1 Diabetes TrialNet, a clinical trial network for type 1 diabetes prevention and early treatment. Their efforts include finding therapies that prevent, reverse, and intervene in the disease at any stage, such as teplizumab. Additionally, they are currently leading research on engineered regulatory T cells (Tregs) as a potential T1D treatment.
Official website here: www.benaroyaresearch.org
Is Benaroya Research Institute At Virginia Mason legitimate?
Benaroya Research Institute At Virginia Mason is a legitimate nonprofit organization registered as a 501(c)(3) entity. Benaroya Research Institute At Virginia Mason submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.
Here are some key statistics you may want to consider:
Executive Compensation: $1,382,774
Professional Fundraising Fees: $0
Other Salaries and Wages: $24,045,459
For more financial information, click here
What is the mission statement of Benaroya Research Institute At Virginia Mason?
The Benaroya Research Institute at Virginia Mason is dedicated to advancing the science that predicts, prevents, reverses, and cures diseases of the immune system. This includes conditions such as autoimmune diseases, allergy, and asthma. The institute's primary focus is on the clinical application of immune tolerance through high-quality clinical trials of emerging therapeutics based on well-established mechanistic hypotheses. The institute leads research aiming to eliminate Type 1 diabetes by finding ways to predict the disease before clinical symptoms occur and identifying therapies that prevent, reverse, and intervene in the disease at any stage. They are also investigating engineered regulatory T cells as a potential T1D treatment. The institute supports collaborative projects involving multiple institutions, such as a recent study on immune system changes upon infection with acute respiratory viral infections in vulnerable populations. Their findings could inform best approaches against COVID-19 for everyone in the future.
Official website here: www.benaroyaresearch.org
Who is the CEO of Benaroya Research Institute At Virginia Mason?
Jane Buckner Md is the President of Benaroya Research Institute At Virginia Mason. The CEO's salary of Benaroya Research Institute At Virginia Mason is $2,366,321 and their total compensation is $2,402,489.
Official website here: www.benaroyaresearch.org
What is the revenue of Benaroya Research Institute At Virginia Mason?
Benaroya Research Institute At Virginia Mason's revenue in 2022 was $94,861,276.
Official website here: www.benaroyaresearch.org
Who are the executives of Benaroya Research Institute At Virginia Mason and what are their salaries?
The average compensation at Benaroya Research Institute At Virginia Mason during 2022 was $70,634. There are 360 employees and 3 volunteers at Benaroya Research Institute At Virginia Mason.
Here are 26 key members and their salaries (Benaroya Research Institute At Virginia Mason's CEO's salary is $2,366,321 and their total compensation is $2,402,489):
- Ketul Patel (Ex-Officio Director, Co-Ceo Vmfh)
- Gary Kaplan (Ex-Officio Director, Co-Ceo Vmfh (Thru 12/31/21))
- Jane Buckner Md (President)
- Margaret Mccormick Phd (Executive Director & Coo)
- William Kwok Phd (Member)
- Steven Ziegler Phd (Director, Academic Affairs)
- Michael Labosier (Cfo)
- Bolong Cao (Director, Business Development)
- Carmen Mikacenic Md (Associate Member)
- Daniel Campbell Phd (Director, Center For Fundamental Immunology)
- Bob Carlile (Director)
- Uli Chi Phd (Director/Chair)
- Sister Jude Connelly Osf (Director)
- Carolyn Corvi (Director)
- Sister Ruth Goodwin Osf (Director)
- Tod Hamachek (Director)
- Michael Hoffman (Director)
- Dennis Hunthausen (Director)
- Karen Lee (Director)
- Robert Lemon (Director/Vice Chair)
- Gregg Meyer Md Msc (Director)
- John Oppenheimer (Director)
- Marvin O'Quinn (Director)
- Diann Puls (Director)
- Miriam Chambliss (Corporate Secretary / Vp Div General Counsel)
- David Nosacka (Treasurer / Svp & Cfo Fhs)
Official website here: www.benaroyaresearch.org
Where can I find the form 990 for Benaroya Research Institute At Virginia Mason?
The Benaroya Research Institute At Virginia Mason’s most recent form 990 was submitted in 2022 and can be accessed here
Official website here: www.benaroyaresearch.org
Learn more at the official website: www.benaroyaresearch.org
Mission Statement of Benaroya Research Institute At Virginia Mason
Benaroya Research Institute At Virginia Mason is a leading scientific organization dedicated to predicting, preventing, reversing, and curing diseases of the immune system. With a primary focus on immune tolerance, this institute has been at the forefront of research in autoimmune diseases, allergy and asthma, and immune-mediated rejection of transplanted solid organs, tissues, and cells since 1999.
The institute's mission is to advance clinical applications of immune tolerance by performing high-quality clinical trials of emerging therapeutics based on well-established mechanistic hypotheses. Benaroya Research Institute At Virginia Mason is the prime recipient of a $27 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), which supports the Immune Tolerance Network (ITN), a research consortium established in 1999. The institute oversees the overall grant, including infrastructure oversight, and coordinates across network activities, tracks progress with respect to network goals, and develops strategies to meet network objectives.
Under the ITN Leadership Group (LG), the institute's principal investigator, Dr. Jerry Nepom, and co-director, Dr. Bill St Clair, oversee a team of academic experts from the University of Michigan, Emory University, Brigham and Women's Hospital, two academic immunologists with expertise in cellular and systems immunology and bioinformatics, and two representatives from each of the ITN therapeutic areas (autoimmunity, transplantation, and allergy). The LG's responsibilities include coordination across network activities, tracking progress with respect to network goals, and developing strategies to meet network objectives.
Impact
This information is meant to be a general summary of Benaroya Research Institute At Virginia Mason. Please take the time to review official sources before making any decisions based upon the content provided here.
Thursday, August 15, 2024
Benaroya Research Institute at Virginia Mason's impact is significant in advancing the science that predicts, prevents, reverses, and cures diseases of the immune system. The institute plays a key role in the Immune Tolerance Network (ITN), focusing on developing new tolerogenic approaches for the treatment and prevention of diseases in areas such as asthma, autoimmune diseases, and immune-mediated rejection of transplanted organs.
Furthermore, the institute is a leader in type 1 diabetes research, actively working towards eliminating the disease by predicting it before clinical symptoms occur and identifying therapies that can prevent or reverse it. Through initiatives like TrialNet, research on teplizumab, and the development of engineered regulatory T cells, Benaroya Research Institute is at the forefront of innovative treatments for type 1 diabetes.
In addition, the institute is involved in studying respiratory viral infections in vulnerable populations, impacting immune system changes upon infection with acute respiratory viral infections. The research conducted by Benaroya Research Institute contributes to the broader scientific community by sharing longitudinal findings with the Human Immunology Project Consortium.
Overall, Benaroya Research Institute's dedication to advancing medical research in immunology has a profound impact on the understanding and treatment of diseases affecting the immune system, benefiting individuals worldwide.
Financials
This financial information is from Propublica.
Other financial information:
This information is from the most recently submitted tax form from this organization, which was in 2022.
- Assets and Liabilities:
Programs
Programs are reported by nonprofits in their tax forms and are normally their tax-exempt activities.
COMMERCIAL STUDIES
Revenue
$4,732,659
CORE SERVICES AND OTHER
Revenue
$553,528
Organization Details
Founding Year
1956
Phone
(206) 342-6500
Principal Officer
Jane Buckner Md
Main Address
1201 NINTH AVENUE, SEATTLE, WA, 98101
Website
www.benaroyaresearch.org
NTEE Category
Code: H90 - Medical research
If you are a representative of Benaroya Research Institute At Virginia Mason and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.